Takeaway

• The introduction of public reimbursement of immuno-oncology (I-O) therapies in Alberta, Canada, led to greater adoption of these therapies for advanced NSCLC and an increase in OS, according to real-world population-based data.

Why this matters

• The findings contribute to the body of evidence of real-world benefits of I-O therapies for...